Printer Friendly

Articles from M2 Pharma (May 16, 2017)

1-29 out of 29 article(s)
Title Author Type Words
70% of Nigerians living in rural areas have no access to good-quality medicines. 287
Agilent Technologies Approved for Expanded Use of PD-L1 IHC 28-8 pharmDx Diagnostic in Europe. 352
Akonni Biosystems Secures USD 4m; Will Accelerate Initiatives, First FDA Submission. 303
Ardelyx reports positive, topline results from the T3MPO-1 trial. Financial report 200
AstraZeneca decreases risk of worsening or death in patients with third stage lung cancer in phase three trial of Imfinzi. 232
Body Vision Medical awarded US FDA clearance for LungVision navigation system to revolutionise the treatment of lung lesions. 212
Boehringer Ingelheim opens new commercial production site for biopharmaceuticals in Shanghai. 189
Boston Scientific buys Symetis SA business for USD435m in cash. 234
Crescita Therapeutics reports Q1 2017 financial results. Financial report 192
Cuba announces new trial for Alzheimer's drug. 302
Dendreon Releases Results of New Proceed Registry Analysis Showing Overall Survival Benefit with Provenge in Metastatic Prostate Cancer. 250
Eli Lilly meets primary endpoint in three phase three studies of Galcanezumab migraine drug. 146
European Commission opens first formal investigation into excessive drug pricing. 638
First Patient Dosed in Phase 1 Clinical Trial of Syros' SY-1365 Selective CDK7 Inhibitor in Patients with Advanced Solid Tumors. 351
Galmed Pharmaceuticals reports Q1 2017 financial results. Financial report 162
Genoa Pharmaceuticals raises USD 62m, Names Montgomery as CEO. 245
Glemark Pharmaceuticals gains US FDA clearance to begin Phase I study of GBR 1342. 200
Global Factor VIII Deficiency Treatment Market to Grow at a CAGR of 5.5% by 2021, Research and Markets Forecasts. 245
Global Transplantation Market to Grow at a CAGR of 9.76% by 2021, Research and Markets Forecasts. 124
Healthcare, Life Sciences IT Firm Emids Opens London Office. 216
Immunomic Therapeutics Licenses Phase II Cancer Immunotherapy Technology from Annias. 396
MabVax Therapeutics anticipates USD4.1m from public offering of common stock & preferred stock. 301
Moriarty Named CFO at AI-Driven Biopharmaceutical Firm twoXAR. 318
Paradigm Biopharmaceuticals reports positive results from hay fever study. 214
Resverlogix Corp's IND application for planned launch of Phase 2a Apabetalone kidney dialysis trial approved by US FDA. 319
Teleflex Starts Phase I Clinical Study of RePlas Freeze-Dried Plasma. 469
US FDA Accepts Aerie Pharmaceuticals' NDA Submission for Rhopressa 0.02%. 552
Voisin Consulting Life Sciences appoints Carole Jones as director of market access. 238
WuXi AppTec purchases HD Biosciences. 172

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters